489 related articles for article (PubMed ID: 29364548)
41. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
42. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
43. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
Kontoyiannis DP; Bassetti M; Nucci M; Capparella MR; Yan JL; Aram J; Hogan PA
Mycoses; 2017 Oct; 60(10):663-667. PubMed ID: 28597967
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
Undre NA; Stevenson P; Freire A; Arrieta A
Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
[TBL] [Abstract][Full Text] [Related]
45. Micafungin injection for the treatment of invasive candidiasis in pediatric patients under 4 months of age.
Abdel-Haq N; Smith SM; Asmar BI
Expert Rev Anti Infect Ther; 2022 Apr; 20(4):493-505. PubMed ID: 34882043
[TBL] [Abstract][Full Text] [Related]
46. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
47. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
48. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
Natarajan G; Lulic-Botica M; Aranda JV
J Perinatol; 2009 Nov; 29(11):738-43. PubMed ID: 19776753
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
50. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Glöckner A
Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
[TBL] [Abstract][Full Text] [Related]
51. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
52. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
53. Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia.
Marcos-Zambrano LJ; Escribano P; Sánchez-Carrillo C; Bouza E; Guinea J
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799221
[TBL] [Abstract][Full Text] [Related]
54. Emergence of Candida tropicalis resistant to caspofungin.
Pasquale T; Tomada JR; Ghannoun M; Dipersio J; Bonilla H
J Antimicrob Chemother; 2008 Jan; 61(1):219. PubMed ID: 18024953
[No Abstract] [Full Text] [Related]
55. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
57. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
58. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Scott LJ
Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
[TBL] [Abstract][Full Text] [Related]
59. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
